167 related articles for article (PubMed ID: 38553466)
1. Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Agostini A; Piro G; Inzani F; Quero G; Esposito A; Caggiano A; Priori L; Larghi A; Alfieri S; Casolino R; Scaglione G; Tondolo V; Cammarota G; Ianiro G; Corbo V; Biankin AV; Tortora G; Carbone C
Nat Commun; 2024 Mar; 15(1):2764. PubMed ID: 38553466
[TBL] [Abstract][Full Text] [Related]
2. Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential.
Sans M; Makino Y; Min J; Rajapakshe KI; Yip-Schneider M; Schmidt CM; Hurd MW; Burks JK; Gomez JA; Thege FI; Fahrmann JF; Wolff RA; Kim MP; Guerrero PA; Maitra A
Cancer Discov; 2023 Aug; 13(8):1844-1861. PubMed ID: 37285225
[TBL] [Abstract][Full Text] [Related]
3. Intraductal papillary mucinous neoplasm.
Shi C; Hruban RH
Hum Pathol; 2012 Jan; 43(1):1-16. PubMed ID: 21777948
[TBL] [Abstract][Full Text] [Related]
4. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
5. Digital spatial profiling of intraductal papillary mucinous neoplasms: Toward a molecular framework for risk stratification.
Iyer MK; Shi C; Eckhoff AM; Fletcher A; Nussbaum DP; Allen PJ
Sci Adv; 2023 Mar; 9(11):eade4582. PubMed ID: 36930707
[TBL] [Abstract][Full Text] [Related]
6. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
Nissim S; Idos GE; Wu B
Pancreas; 2012 Nov; 41(8):1195-205. PubMed ID: 22750975
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes associated with the progression of intraductal papillary mucinous neoplasms.
Jury RP; Thibodeau BJ; Fortier LE; Geddes TJ; Ahmed S; Pruetz BL; Farinola MA; Wilson GD
Pancreas; 2012 May; 41(4):611-8. PubMed ID: 22273699
[TBL] [Abstract][Full Text] [Related]
8. Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).
Zhang C; Al-Shaheri FN; Alhamdani MSS; Bauer AS; Hoheisel JD; Schenk M; Hinz U; Goedecke P; Al-Halabi K; Büchler MW; Giese NA; Hackert T; Roth S
Clin Cancer Res; 2023 Apr; 29(8):1535-1545. PubMed ID: 36516200
[TBL] [Abstract][Full Text] [Related]
9. MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages.
Kato H; Tateishi K; Fujiwara H; Nakatsuka T; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Otsuka M; Iwadate D; Oyama H; Kanai S; Noguchi K; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito K; Saito T; Takahara N; Kishikawa T; Hamada T; Takahashi R; Miyabayashi K; Mizuno S; Kogure H; Nakai Y; Hirata Y; Toyoda A; Ichikawa K; Qu W; Morishita S; Arita J; Tanaka M; Ushiku T; Hasegawa K; Fujishiro M; Koike K
Gastroenterology; 2022 Apr; 162(4):1272-1287.e16. PubMed ID: 34953915
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
11. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
[TBL] [Abstract][Full Text] [Related]
12. Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.
Satoh K; Hamada S; Kanno A; Hirota M; Umino J; Ito H; Masamune A; Egawa S; Unno M; Shimosegawa T
J Gastroenterol; 2010 Jul; 45(7):763-70. PubMed ID: 20107842
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of cdx2 homeobox gene in intraductal papillary-mucinous neoplasm of the pancreas but not in pancreatic ductal adenocarcinoma.
Yeh TS; Ho YP; Chiu CT; Chen TC; Jan YY; Chen MF
Pancreas; 2005 Apr; 30(3):233-8. PubMed ID: 15782100
[TBL] [Abstract][Full Text] [Related]
14. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
15. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
Eckhoff AM; Brown MC; Landa K; Naqvi I; Holl EK; Boczkowski D; Fletcher A; Rhodin KE; Giang MH; Sullenger B; Beasley GM; Allen PJ; Nair SK
Front Immunol; 2023; 14():1116034. PubMed ID: 37575220
[TBL] [Abstract][Full Text] [Related]
16. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature.
Eckhoff AM; Fletcher AA; Landa K; Iyer M; Nussbaum DP; Shi C; Nair SK; Allen PJ
Ann Surg Oncol; 2022 Nov; 29(12):7781-7788. PubMed ID: 35831529
[TBL] [Abstract][Full Text] [Related]
18. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
19. Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression.
Durante S; Vecchiarelli S; Astolfi A; Grassi E; Casadei R; Santini D; Panzacchi R; Ricci C; Serravalle S; Tarantino G; Falconi M; Teti G; Indio V; Pession A; Minni F; Biasco G; Di Marco M
Oncotarget; 2016 Nov; 7(46):74797-74806. PubMed ID: 27566563
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
